Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.
IPO Year: 2021
Exchange: NASDAQ
Website: inspira-technologies.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/1/2021 | $9.00 → $10.00 | Buy | Aegis Capital |
| 8/26/2021 | $9.00 | Buy | Aegis Capital |
RA'ANANA, ISRAEL, Jan. 17, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira" or the "Company"), a leader in life-support technology innovation, has announced that the Company is establishing a dedicated production line for a crucial component of its innovative respiratory support system, in collaboration with Zriha Medical Ltd ("Zriha Medical"), a leading international manufacturer specializing in medical device production. The collaboration involves the manufacture of a flow mechanism that will be integrated into Inspira's products for use in the extracorporeal circulation of blood during the oxygenation process. Zriha Medical's capabilities and pre
The technology has the potential to provide life-saving support for the approximately 20 million ICU patients with respiratory failure annually RA'ANANA, Israel, Jan. 14, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira" or the "Company"), a leader in life-support technology innovation, is proud to announce the development of a modular configuration for its groundbreaking VORTX blood oxygenation delivery technology. We believe that this innovative approach represents a significant advancement in the field of extracorporeal oxygenation and has the potential to transform critical care practices worldwide. The unique modular configuration of the VORTX b
RA'ANANA, Israel, Jan. 10, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, announced today that it is preparing for a potential production ramp-up of its INSPIRA™ ART100 device. This strategic readiness comes in light of the recent outbreak of human metapneumovirus (hMPV) in China, which has highlighted the growing need for advanced respiratory care technologies globally. Inspira is already in discussions with leading providers in affected regions to evaluate demand for advance respiratory solutions and deployment of the INSPIRA™ ART100 device, ensuring rapid response capabil
Visitors at Glo-Med Network Inc's booth can explore Inspira's cutting-edge respiratory solutions, with the FDA-cleared INSPIRA™ ART100, showcasing the future of respiratory care RA'ANANA, Israel, Jan. 7, 2025 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW), ("Inspira Technologies," "Inspira" or the "Company"), a groundbreaking respiratory support technology company, is pleased to announce that the INSPIRA™ ART100, a cardiopulmonary bypass system will be showcased at Arab Health 2025, one of the largest healthcare exhibitions in the Middle East, expected to have over 3,800 exhibitors and over 180 visiting countries. The event will take place from January 2
RA'ANANA, Israel, Dec. 27, 2024 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN), (NASDAQ:IINNW), ("Inspira Technologies," "Inspira" or the "Company"), a groundbreaking respiratory support technology company, a pioneer in life-support technology, today announced the pricing of a private placement offering consisting of the issuance and sale of 4,608,715 ordinary shares, no par value per share (or pre-funded warrants in lieu thereof) and ordinary warrants to purchase up to 4,608,715 ordinary shares, at a combined purchase price of $0.70. The ordinary warrants have a term of eighteen months and have an exercise price of $1.10 per share. The Company intends to use the net
RA'ANANA, Israel, Dec. 16, 2024 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN, IINNW)), ("Inspira Technologies," "Inspira" or the "Company"), a groundbreaking respiratory support technology company, announced the delivery of INSPIRA™ ART100 systems to its U.S. distributor, Glo-Med Networks Inc ("Glo-Med"). The systems were shipped in fulfilment of a purchase order issued by Glo-Med to Inspira. The delivered INSPIRA™ ART100 systems will be distributed to sales targets across hospitals on the U.S. east coast and distributed to a cardiothoracic surgery division at a leading New York hospital, ranked among the top 15 percent of cardiothoracic programs in the U.S., with a vie
RA'ANANA, Israel, Dec. 10, 2024 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN, IINNW)), ("Inspira Technologies" or the "Company"), a groundbreaking life support technology company, revealed the expansion of its HYLA blood sensor technology ("HYLA") into an immediate personalized Blood Lab Test, aimed at performing real-time patient blood work for the rapid detection in minutes of the potential development of an underlying life-threatening medical condition. The HYLA business model is designed to replace the need for nurses to take intermittent physical blood samples from patients undergoing extracorporeal procedures by providing patient blood work with pre-determined set
RA'ANANA, Israel, Dec. 4, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN), (Nasdaq: IINNW) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking life support technology company, entered into a strategic collaboration with Westchester Medical Center in Valhalla, New York. Westchester Medical Center, the flagship hospital in the Westchester Medical Center Health Network, will evaluate the performance and effectiveness of the new U.S. Food and Drug Administration (FDA) cleared INSPIRA ART100 systems in various real-world clinical scenarios, exposing Inspira's products and technologies to leading physicians and medical institutions. The strategic colla
RA'ANANA, Israel, Nov. 8, 2024 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN), ("Inspira Technologies" or the "Company"), an innovative medical technology company in the life support and respiratory treatment arena, is pleased to invite investors to a webinar on November 11, 2024, at 4:15 p.m. EST. The exclusive event, hosted by RedChip Companies, will feature Joe Hayon, President of Inspira Technologies, who will highlight the Company's developments, including its development of innovative life support technology, designed to monitor and elevate declining blood oxygen saturation levels in minutes without mechanical ventilation, that could disrupt the $19 billion mec
In the news release, Inspira™ Announces Establishment of Distribution Facility to Support U.S. Deployment of INSPIRA™ ART100, issued 24-Oct-2024 by Inspira Technologies over PR Newswire, we are advised by the company that the first paragraph, should read "Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW))) ("Inspira Technologies", "Inspira" or the "Company"), a groundbreaking life support technology company, is pleased to announce that it has entered into an agreement with Glo-Med Networks Inc ("Glo-Med"), which will serve as Inspira's primary distributor in the United States. Glo-Med's distribution facility will serve as a support center for the deployment of the INSPIRA ART100 in
Aegis Capital reiterated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $10.00 from $9.00 previously
Aegis Capital initiated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $9.00
6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
F-3 - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
D - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
144 - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)
6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
RA'ANANA, Israel, Dec. 11, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board. Dr. Gorfil is a distinguished specialist in cardiac surgery and intensive care medicine. Dr. Gorfil is both the head of the Cardiothoracic Surgery Intensive Care Unit and the Extracorporeal Membrane Oxygenation program at the Department of Cardiothoracic Surgery at Rabin Medical Center, Israel. Dr. Gorfil's expertise are expected to significantly contribute to the
Dr. Nir is a clinical strategy expert with market experience RA'ANANA, Israel, May 30, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, has announced the appointment of Dr. Adi Rizansky Nir, PhD to the position of Chief Medical Officer ("CMO"). Dr. Nir brings a wealth of expertise and a distinguished track record in the field of medicine and healthcare administration to the Company. As CMO, Dr. Nir will play a critical role in overseeing and guiding Inspira's medical operations and strategic initiatives. With an unwavering commitment to patient care, inn
RA'ANANA, Israel, Aug. 10, 2021 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) (the "Company"), a specialty medical device company engaged in the research, development, manufacturing, and marketing of proprietary respiratory support technologies, today announced the appointment of Lior Amit, CPA, to the Company's board of directors. Mr. Amit has extensive business and go-to-market experience to further support Inspira's planned future deployment and market penetration of the Augmented Respiration Technology (ART) system. For more than 17 years, Mr. Amit served as the CFO of the BBR Saatchi & Saatchi advertising group in Israel, playing a vital role in the
SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)
SC 13G - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)
SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)
SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)
SC 13G - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)
SC 13G - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)
Company to aggressively promote INSPIRA™ ART100 in the U.S. and additional markets following FDA clearance, as well as accelerate plans for ground-breaking INSPIRA™ ART (Gen2) RA'ANANA, Israel, June 20, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN), (NASDAQ:IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced today that the Company's President and co-founder, Mr. Joe Hayon, presented a business plan with targets for the Company's next-generation technologies on a Company conference call today. On the call, Inspira unveiled plans to build an opportunity for a share of the $19 billion mechanical ventilation market. Inspira's
The event is an opportunity to present and demonstrate new products and technologies to potential customers and strategic partners RA'ANANA, Israel, June 5, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, is proud to announce plans to exhibit the INSPIRA™ ART100 System, recently cleared by the U.S. Food and Drug Administration ("FDA"), at the Extracorporeal Life Support Organization (ELSO) conference in Detroit, Michigan between September 29 to October 1, 2024. This event provides the Company with an opportunity to present the system in front of healthcare representa
RA'ANANA, Israel, May 30, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW))) (the "Company" or "Inspira") a breakthrough medical technology company, announced today that Company President, Director, and co-founder, Mr. Joe Hayon, will discuss the Company's business targets, distribution agreements and next steps in a conference call to be held at 9:00am Eastern Time on Thursday, June 20, 2024. This follows the significant milestone of receiving FDA clearance for the INSPIRA™ ART100 system, as announced on May 28, 2024. Event Details: Date: Thursday, June 20, 2024 Time: 9:00 am Eastern Time Speaker: Joe Hayon, President, Director, and Co-Founder Attendance Info
FDA Submission for approval of INSPIRA™ ART100 95% Accuracy Results for HYLA™ Blood Sensor Compared to Standard Blood Gas Analyzers Granted U.S. Patent for INSPIRA™ ART Medical Device RA'ANANA, Israel, March 25, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, today announced its financial results for the year ended December 31, 2023. Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, commented, "In 2023, we achieved significant progress in diversifying our business development to ensure continuous growth, reaching very important milestones that we believ
The major milestone refers to Inspira's proprietary technology to oxygenate blood for the INSPIRA™ ART (Gen 2). This patented tech is considered by Inspira to be a game-changer and also aims to replace technologies used today by current medical device companies.Anticipated U.S. Food and Drug Administration (FDA) Clearance for INSPIRA™ ART100 (Gen 1) in the first half of 2024, to address the $1.16 Billion perfusion systems market.RA'ANANA, Israel, March 4, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced today that the Company's President, and co-founder, Mr. Joe Hayon, p
RA'ANANA, Israel, Feb. 27, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, announced today that the Company President, Director and co-founder, Mr. Joe Hayon, will present an Investor Presentation and announce the Company's next major milestone. The conference call is to be held at 9:00am Eastern Time on Monday, March 4, 2024. To attend the conference call, please enter: link Inspira Technologies OXY B.H.N. Ltd. Inspira™ Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Re
ORLANDO, FL / ACCESSWIRE / May 5, 2023 / RedChip Companies will air new interviews with Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW))) and Genius Group Limited (NYSE:GNS) on The RedChip Money Report® on Bloomberg TV, this Saturday, May 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Inspira Technologies: https://www.redchip.com/assets/iinn_interview_accessGenius Group: https://www.geniusuinfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experien
ORLANDO, Fla, Dec. 22, 2022 /PRNewswire/ -- RedChip Companies will air an interview with Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, on The RedChip Money Report® on Bloomberg TV, this Saturday, December 24, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Interview Highlights: In the exclusive RedChip Money Report interview, Inspira™ Technologies' Co-Founder & President, Joe Hayon discusses how Inspira's technology could reduce the need for invasive mechanical ventilation, plans to begin human studies at leading medi
ORLANDO, FL / ACCESSWIRE / December 22, 2022 / RedChip Companies will air a new interview with Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, on The RedChip Money Report® on Bloomberg TV, this Saturday, December 24, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Inspira™ Technologies' Co-Founder & President Joe Hayon discusses how Inspira's technology could reduce the need for invasive mechanical ventilation, plans to begin human studies at leading m
ORLANDO, FL / ACCESSWIRE / October 21, 2022 / RedChip Companies will air a new interview with Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN)(NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, on The RedChip Money Report® on Bloomberg TV, this Saturday, October 22, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Inspira™ Technologies' President, Director, and Co-Founder Joe Hayon discusses the Company's InspiraTMART System and HYLA blood sensor, the multi-billion-dollar market opportunity both technolog